The SYNCHRONIZE-CVOT trial, published November 9, 2026, in The Lancet, demonstrated that the investigational drug survodutide does not increase the risk of major cardiovascular events in adults with obesity.
While the drug demonstrated significant weight loss and metabolic improvements, it did not show superior cardioprotection compared to a placebo.
In this phase 3 trial, involving 5,530 participants across 34 countries, researchers assessed whether survodutide—a dual agonist of the GLP-1 and glucagon receptors—posed cardiovascular risks. The study met its primary endpoint of non-inferiority. The composite cardiovascular outcome, which included cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, revascularization related to ischemia, and heart failure events, occurred in 3.7% of the survodutide group compared to 4.1% in the placebo group (HR 0.89; 95% CI 0.67–1.18).
Because the trial was specifically designed to evaluate safety rather than prove a cardioprotective effect, the lack of statistical superiority over the placebo was an expected outcome for the primary objective.
Beyond cardiovascular safety, the trial highlighted meaningful changes in body composition and metabolic markers. At week 72, participants receiving 3.6 mg and 6.0 mg of survodutide achieved average weight reductions of 9.3% and 9.7%, respectively, outpacing the 2.4% reduction seen in the placebo arm. These findings suggest a mechanism of action for weight management, supported by reductions in systolic blood pressure and inflammatory markers like high-sensitivity C-reactive protein.
| Metric (at Week 72) | Survodutide (3.6 mg) | Survodutide (6.0 mg) | Placebo |
|---|---|---|---|
| Body Weight Reduction | 9.3% | 9.7% | 2.4% |
| Systolic BP Reduction | -2.57 mmHg | -3.17 mmHg | Baseline |
| Gastrointestinal Adverse Events | 48% (Nausea) | 49% (Nausea) | 12.1% (Nausea) |
The data also indicated a potential protective effect against the onset of type 2 diabetes. Among participants without diabetes at baseline, the incidence of the disease was lower in the treated groups (1.1%) compared to those receiving the placebo (3.6%). However, researchers noted that these metabolic benefits must be weighed against the tolerability of the drug, particularly regarding gastrointestinal side effects.
The trial reported a higher frequency of gastrointestinal events, primarily nausea and vomiting, during the initial dose-escalation phase. Data showed that 19.3% of the 3.6 mg group and 20.8% of the 6.0 mg group discontinued the treatment specifically due to these adverse events, compared to only 1.9% in the placebo arm. The researchers noted that the dose-escalation protocol may have contributed to these high rates of discontinuation.
The impact on heart failure symptom scores did not reach statistical significance (p=0.080). The study was funded by Boehringer Ingelheim, which played an active role in trial design and data analysis.
- The Lancet: SYNCHRONIZE-CVOT primary results and cardiovascular safety endpoints (2026).
- PubMed/Medline: Clinical review of GLP-1 and glucagon receptor dual agonism in obesity management.
- World Health Organization: Global obesity and cardiovascular disease epidemiological data.
